Newtek商业服务 NEWT 深 沪
交易中 08-04 11:12:50 美东时间
11.36
+0.160
+1.43%
华盛通- 最 高11.365
- 今 开11.32
- 成交量 2.83万股
- 最 低 11.2401
- 昨 收 11.20
- 总市值 2.99亿
- 52周最高 14.92
- 市盈率 静 5.81
- 换手率 0.11%
- 52周最低 8.74
- 委 比 -9.91%
- 总股本 2634.20万
- 历史最高 31.52
- 量 比 0.31
- 振 幅 1.12%
- 历史最低 -16.382
- 每 手 1
- 风险率 1.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NewtekOne amends revolving credit facility with Capital One
NewtekOne (NASDAQ:NEWT) announced on Tuesday the amendment of a revolving credit facility, which aims to fund the origination of alternative loan program loans before they are placed into securitizati...
07-29 21:14
Piper Sandler Maintains Neutral on NewtekOne, Raises Price Target to $12
Piper Sandler analyst Crispin Love maintains NewtekOne (NASDAQ:NEWT) with a Neutral and raises the price target from $11.5 to $12.
07-29 20:08
NewtekOne Affirms FY2025 GAAP EPS Guidance of $2.10-$2.50 vs $2.24 Est
NewtekOne (NASDAQ:NEWT) affirms FY2025 GAAP EPS guidance from $2.10-$2.50 to $2.10-$2.50 vs $2.24 analyst estimate..
07-29 04:18
NewtekOne Q2 EPS $0.52 Misses $0.53 Estimate, Sales $70.198M Miss $73.885M Estimate
NewtekOne (NASDAQ:NEWT) reported quarterly earnings of $0.52 per share which missed the analyst consensus estimate of $0.53 by 1.33 percent. This is a 20.93 percent increase over earnings of $0.43 per share from the same
07-29 04:01
苹果、微软、亚马逊、Meta财报来袭
作者丨Oliver Rodzianko 编译 | 华尔街大事件 本周科技巨头、能源巨头、金融公司、医疗保健行业领袖和消费者品牌将陆续发布大量财报。 焦点将集中...
07-28 20:40
Earnings Scheduled For July 28, 2025
Companies Reporting Before The Bell • Bank of Hawaii (NYSE:BOH) is likely to re...
07-28 16:32
A Glimpse of NewtekOne's Earnings Potential
NewtekOne (NASDAQ:NEWT) is gearing up to announce its quarterly earnings on Mon...
07-26 01:02
韩国市场开始狂飙：动辄单日翻倍，Upbit日交易量破百亿美元
转载来源：火讯财经 文章来源： Zen 作者：Zen，PANews 7月，沉寂的韩国虚拟资产市场正式复苏，迎来了一次“量价齐升”的爆发行情...
07-24 23:55
Keefe, Bruyette & Woods Maintains Market Perform on NewtekOne, Lowers Price Target to $12
Keefe, Bruyette & Woods analyst Timothy Switzer maintains NewtekOne (NASDAQ:NEWT) with a Market Perform and lowers the price target from $13 to $12.
07-11 23:49
Traws Pharma Seeks FDA Guidance On TXM For Bird Flu; Submits Phase 2 Studies For TXM, Ratutrelvir In Flu And COVID
Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern HemisphereBriefing documents submitted to FDA for a Type D meeting request to continue
06-30 18:45
